Secondary outcomes included improved pulmonary function, weight gain, and olfactory recovery.<h4>Conclusion</h4>This review demonstrates that CFTR modulators provide significant benefits for sinonasal disease in CF, reinforcing their role as a comprehensive therapeutic approach addressing both upper airway and systemic disease burdens. The gene discussed is CFTR; the disease is cystic fibrosis.